NIIMBL Launches Viral Vector Program to Improve Access to AAV Gene Therapy

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) officially launches the Viral Vectors NIIMBL-led Program focused on developing and making broadly available robust, economically viable, shared manufacturing process and analytical platforms for Adeno-Associated Virus (AAV) gene therapy vectors. NIIMBL has committed to this effort with an ultimate vision to provide access to high quality viral vectors capable of serving the full spectrum of patient need, from prevalent indications to ultra-rare diseases, without cost or speed limitations.